Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Research Grant, 2013
    Alpha-Synuclein-Expression-Lowering Therapeutics: Initial Pre-Clinical Development

    Objective/Rationale:             
    Increased dosage of the alpha-synuclein gene is linked to Parkinson’s disease (PD). Out of 1,126 FDA-approved compounds and health supplements screened, we identified...

  • Rapid Response Innovation Awards, 2013
    BL-OG: A Novel, Minimally-Invasive and Homeostatic Method for Selective Regulation of Neural Dynamics in the Subthalamic Nucleus

    Objective/Rationale:             
    Altered neural activity in the subthalamic nucleus (STN) is believed to be key to Parkinson’s disease. Accordingly, deep-brain stimulation (DBS) delivered to the STN...

  • Biosample and Tissue Resource, 2013
    Relationship of Vitamin B12 Status and Parkinson's Disease

    Objective/Rationale:             
    Vitamin B12 deficiency can cause a number of neurological symptoms, including instability, neuropathy (which may cause numbness and tingling) and cognitive defects...

  • Research Grant, 2013
    Cutaneous Alpha-Synuclein Deposition — A Biomarker in Parkinson’s Disease

    Objective/Rationale:             
    There is an unmet need for a biomarker in Parkinson’s disease (PD). Accumulating evidence suggests that deposition of alpha-synuclein, the pathological hallmark of PD...

  • Rapid Response Innovation Awards, 2013
    Creation of the “BiSyn” Model: a Novel Tool to Monitor Alpha-synuclein Aggregation

    Objective/Rationale:             
    The cause of Parkinson’s disease (PD) is unknown. However, it has become clear that the abnormal aggregation of a neuronal protein called alpha-synuclein has an...

  • Biosample and Tissue Resource, 2013
    Alpha-synuclein Three Prime Untranslated Region (3’UTR) Modulation in Parkinson's Disease

    Objective/Rationale:             
    New technology shows that many genes are transcribed (the first step in genetic expression) as multiple, different forms of RNA (molecules that play a role in genetic...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.